QGA
EFTRW

Q Global Advisors’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Q Global Advisors’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-200,000
Closed -$200K – 166
2021
Q2 		$200K Buy
+200,000
New +$162K 0.14% 78

Other funds holding EFTRW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Q Global Advisors's EFTRW Position: Q3 2021 in Review

Q Global Advisors sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2021, closing a stake of 200,000 shares — an estimated $200K sold.

Q Global Advisors first reported a position in EFTRW in Q2 2021 and held it in 1 quarter. The position peaked at $200K in Q2 2021. 21 funds tracked by Wall St. Rank hold EFTRW as of Q3 2021.

  • Q Global Advisors reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
  • Q Global Advisors sold 200,000 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2021, an estimated $200K.
  • Q Global Advisors first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q2 2021 and held it in 1 quarter.
  • Q Global Advisors's eFFECTOR Therapeutics, Inc. Warrant position peaked at $200K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2021.

Based on Q Global Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.